AngioDynamics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended May 31, 2024
July 16, 2024 at 04:00 pm IST
Share
AngioDynamics, Inc. reported earnings results for the fourth quarter and full year ended May 31, 2024. For the fourth quarter, the company reported sales was USD 70.98 million compared to USD 91.07 million a year ago. Net loss was USD 13.45 million compared to USD 21.47 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.54 a year ago. Diluted loss per share from continuing operations was USD 0.33 compared to USD 0.54 a year ago.
For the full year, sales was USD 303.91 million compared to USD 338.75 million a year ago. Net loss was USD 184.35 million compared to USD 52.44 million a year ago. Basic loss per share from continuing operations was USD 4.59 compared to USD 1.33 a year ago. Diluted loss per share from continuing operations was USD 4.59 compared to USD 1.33 a year ago.
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
ANGIODYNAMICS, INC. 
